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Guidelines summarize and evaluate all evidence available, at
the time of the writing process, on a particular issue.
Guidelines and recommendations should help physicians to
make decisions in their daily practice. The level of evidence
and the strength of recommendation of particular treatment
options were weighed and graded according to predeﬁned
scales, as outlined in Tables 1 and 2.Table 1 – Classes of recommendations.
Classes of
recommendations
Deﬁnition 
Class I Evidence and/or general agreement that a 
is beneﬁcial, useful, effective
Class II Conﬂicting evidence and/or divergence of o
efﬁcacy of the given treatment or procedur
Class IIa Weight of evidence/opinion is in favour of 
Class IIb Usefulness/efﬁcacy is less well established
Class III Evidence or general agreement that the giv
not useful/effective, and in some cases ma2. Introduction
These guidelines should be applied to patients with stable
known or suspected coronary artery disease (SCAD): (i) those
having stable angina pectoris or other symptoms felt to be
related to coronary artery disease (CAD) such as dyspnoea; (ii)
those previously symptomatic with known obstructive or non-
obstructive CAD, who have become asymptomatic with
treatment; (iii) those who report symptoms for the ﬁrst timeSuggested wording to use
given treatment or procedure Is recommended/is indicated
pinion about the usefulness/
e
usefulness/efﬁcacy Should be considered
 by evidence/opinion May be considered
en treatment or procedure is
y be harmful
Is not recommended
Table 4 – Traditional clinical classification of chest pain.
Typical angina Meets all three of the following characteristics:
 substernal chest discomfort of characteristic
quality and duration;
 provoked by exertion or emotional stress;
 relieved by rest and/or nitrates within minutes.
Atypical angina
(probable)
Meets two of these characteristics
Non-anginal
chest pain
Lacks or meets only one or none of the
characteristics
Table 2 – Levels of evidence.
Level of evidence A Date derived from multiple randomized
clinical trials or meta-analyses
Level of evidence B Date derived from a single randomized
clinical trial or large non-randomized
studies
Level of evidence C Consensus of opinion of the experts
and/or small studies, retrospective
studies, registries
Table 3 – Main features of stable coronary artery disease.
Pathogenesis
Stable anatomical atherosclerotic and/or functional
alterations of epicardial vessels and/or microcirculation
Natural history
Stable symptomatic or asymptomatic phases which may be
interrupted by ACS
Mechanisms of myocardial ischaemia
 Fixed or dynamic stenoses of epicardial coronary arteries;
 Microvascular dysfunction;
 Focal or diffuse epicardial coronary spasm;
 The above mechanisms may overlap in the same patient and
change over time.
Clinical presentations
Effort induced angina caused by:
 epicardial stenoses;
 microvascular dysfunction;
 vasoconstriction at the site of dynamic stenosis;
 combination of the above.
Rest angina caused by:
 Vasospasm (focal or diffuse);
 epicardial focal;
 epicardial diffuse;
 microvascular;
 combination of the above.
Asymptomatic:
 because of lack of ischaemia and/or of LV dysfunction;
 despite ischaemia and/or LV dysfunction.
Ischaemic cardiomyopathy
ACS, acute coronary syndrome; LV, left ventricular; SCAD, stable
coronary artery disease.
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(for instance because history-taking reveals that similar
symptoms were already present for several months) [1].
3. Deﬁnitions and pathophysiology
Stable coronary artery disease is generally characterized by
episodes of reversible myocardial demand/supply mismatch,
related to ischaemia or hypoxia, which are usually inducible
and reproducible by exercise, emotion or other stress, but may
also be occurring spontaneously. Such episodes of ischaemia/
hypoxia are commonly associated with transient chest
discomfort (angina pectoris). SCAD also includes the stabi-
lized, often asymptomatic, phases that follow an ACS. The
various clinical presentations of SCAD are associated with
different underlying mechanisms that mainly include: (i)
plaque-related obstruction of epicardial arteries; (ii) focal or
diffuse spasm of normal or plaque-diseased arteries; (iii)
microvascular dysfunction and (iv) left ventricular dysfunction
caused by prior acute myocardial necrosis and/or hibernation
(ischaemic cardiomyopathy) (Table 3).
4. Epidemiology
The prevalence of angina in population-based studies
increases with age in both sexes, from 5 to 7% in women
aged 45–64 years to 10–12% in women aged 65–84 and from 4 to
7% in men aged 45–64 years to 12–14% in men aged 65–84.
Epidemiological data on microvascular angina and vasospastic
angina are missing.
5. Natural history and prognosis
Estimates for annual mortality rates range from 1.2 to 2.4% per
annum, with an annual incidence of cardiac death between
0.6 and 1.4% and of non-fatal myocardial infarction (MI) between
0.6% and2.7%.The outcome is worse inpatients with reduced left
ventricular ejection fraction, heart failure, a greater number of
diseased vessels, more proximal locations of coronary stenoses,
greater severity of lesions, more extensive ischaemia, more
impaired functional capacity, older age and more severe angina.
6. Diagnosis and assessment
The diagnosis and assessment of SCAD involves clinical
evaluation, including biochemical risk factors and speciﬁccardiac investigations such as stress testing or coronary
imaging. These investigations may be used to conﬁrm the
diagnosis of ischaemia in patients with suspected SCAD, assist
in stratifying risk associated with the disease and to evaluate
the efﬁcacy of treatment.
6.1. Symptoms and signs
The characteristics of discomfort caused by myocardial
ischaemia is usually located in the chest, near the sternum,
but may be felt anywhere from the epigastrium to the lower
jaw or teeth, between the shoulder blades or in either arm to
the wrist and ﬁngers. The discomfort is often described as
pressure, tightness or heaviness; sometimes strangling,
constricting or burning. Deﬁnitions of typical and atypical
angina are summarized in Table 4.
The Canadian Cardiovascular Society classiﬁcation is
widely used as a grading system for stable angina, to quantify
Table 5 – Classification of angina severity according to the Canadian Cardiovascular Society.
Class I Ordinary activity does not cause angina such as walking and climbing stairs. Angina with strenuous or rapid or prolonged
exertion at work or recreation
Class II Slight limitation of ordinary activity. Angina on walking or climbing stairs rapidly, walking or stair climbing after meals, or in
cold, wind or under emotional stress, or only during the ﬁrst few hours after awakening. Walking more than two blocks on
the level and climbing more than ﬂight of ordinary stairs at a normal pace and in normal conditions
Class III Marked limitation of ordinary physical activity. Angina on walking one to two blocksa on the level or one ﬂight of stairs in
normal conditions and at a normal pace
Class IV Inability to carry on any physical activity without discomfort – angina syndrome may be present at rest
a Equivalent to 100–200 m.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 2 5 9 – e 2 7 3e262the threshold at which symptoms occur in relation to physical
activities (Table 5).
6.1. Non-invasive cardiac investigations
The optimal use of resources is only achieved if pre-test
probabilities based on simple clinical ﬁndings are taken into
consideration before selecting non-invasive cardiac investiga-
tions. Once the diagnosis of SCAD has been made, further
management decisions largely depend on the severity of
symptoms, the patient's risk for adverse cardiac events and
on patient preferences. Ideally, decisions about diagnostic and
therapeutic management should be made together with the
patient who needs comprehensible information about risks and
beneﬁts.
6.2.1. Basic testing
This includes standard laboratory biochemical testing, a
resting ECG, resting echocardiography (Table 6), possibly
ambulatory ECG monitoring (Table 7), and, in selected
patients, a chest X-ray. If there is a clinical suspicion of CADTable 7 – Ambulatory electrocardiogram monitoring for
initial diagnostic assessment of stable coronary artery
disease.
Recommend atio ns Class  Level 
Ambulatory ECG monitoring is r ecom mend ed in 
patients with SCAD and suspe cted arrhyth mia.
I C
Ambulatory ECG monitoring shou ld be cons idered in
patients w ith su spected vasospast ic angina.
IIa C
ECG = electrocardiogram; SCAD = stable coronary artery disease.
Table 6 – Echocardiography.
Recommend atio ns Class a Level b
A rest ing transthoracic echoca rdiogram  is
recom mend ed in all patients fo r:
a)  exclusion of altern ative ca uses  of  angina;
b) regional wall motion abno rmali ties suggest ive of 
CAD;
c) measu rement o f LVEF for risk stratifi cation pu rpose
d) evaluation of di asto lic function
I B
Ultrasound of th e carotid art eri es shou ld be considered
to be performed  by adaequate ly trained  clinicians  to 
IIa C
dete ct increa sed IMT  and/or plaqu e in patients w ith 
suspected S CAD  without known  athe rosclerotic disease  
CAD = coronary artery disease; IMD = intima-media thickness;
LVEF = left ventricular ejection fraction; SCAD = stable coronary
artery disease.
aClass of recommendation.
bLevel of evidence.instability, biochemical markers of myocardial injury—such as
troponin T or troponin I—should be measured, preferably
using high sensitivity or ultrasensitive assays. If troponin is
elevated, further management should follow the non-ST-
elevation acute coronary syndrome (NSTE-ACS) guidelines.
6.2.2. Three major steps used for decision-making
Step I is the determination of the pre-test probability. In patients
with intermediate probability step 2 consists of non-invasive
testing to establish the diagnosis of SCAD including non-
obstructive atherosclerosis. The latter may also be useful in
patients with a PTP for SCAD < 15% but intermediate probability
of atherosclerosis e.g. measured by SCORE system. Step 3
consists of stratifying for risk of subsequent events usually on
the basis of available non-invasive tests in patients at inter-
mediate PTP. Usually, optimal medical therapy will be instituted
between steps 2 and 3. In patients with severe symptoms who
have a high-intermediate or high pre-test probability of disease,
early invasive coronary angiography (ICA) with appropriate
invasive conﬁrmation of the signiﬁcance of a stenosis (usually
by FFR) and subsequent revascularization may be appropriate
bypassing non-invasive testing in steps 2 and 3.
6.2.3. Principles of diagnostic testing
As non-invasive, imaging-based diagnostic methods for
detecting SCAD have typically sensitivities and speciﬁcitiesTable 8 – Characteristics of tests commonly used to
diagnose the presence of coronary artery disease.
Sensitivity Speciﬁcity
Exercise ECGa 45–50 85–90
Exercise stress echocardiography 80–85 80–88
Exercise stress SPECT 73–92 63–87
Dobutamine stress echocardiography 79–83 82–86
Dobutamine stress MRIb 79–88 81–91
Vasodilator stress echocardiography 72–79 92–95
Vasodilator stress SPECT 90–91 75–84
Vasodilator stress MRIb 67–94 61–85
Coronary CTAc 95–99 64–83
Vasodilator stress PET 81–97 74–91
CAD = coronary artery disease; CTA = computed tomography an-
giography; ECG = electrocardiogram; MRI = magnetic resonance
imaging; PET = positron emission tomography; SPECT = single
photon emission computed tomography.
a Results without/with minimal referral bias.
b Results obtained in populations with medium-to-high preva-
lence of disease without compensation for referral bias.
c Results obtained in populations with low-to-medium prevalence
of disease.
Table 9 – Clinical pre-test probabilitiesa in patients with
stable chest pain symptoms.
Age Typical
angina
Atypical
angina
Non-anginal
pain
Men Women Men Women Men Women
30–39 59 28 29 10 18 5
40–49 69 37 38 14 25 8
50–59 77 47 49 20 34 12
60–69 84 58 59 28 44 17
70–79 89 68 69 37 54 24
>80 93 76 78 47 65 32
ECG = electrocardiogram; PTP = pre-test probability (%); SCAD =
stable coronary artery disease.
a Probabilities of obstructive coronary disease shown reﬂect the
estimates for patients aged 35, 45, 55, 65, 75 and 85 years.
Groups with a PTP < 15% can be managed without further testing.
Groups with a PTP of 15–65% could have an exercise ECG if feasible
as the initial test. However, if local expertise and availability permit
a non-invasive imaging based test for ischaemia this would be
preferable given the superior diagnostic capabilities of such tests.
In young patients radiation issues should be considered.
Groups with a PTP between 66 and 85% should have a non-invasive
imaging functional test for making a diagnosis of SCAD.
In groups with a PTP > 85% and one can assume that SCAD is
present. They need risk stratiﬁcation only.
Table 10 – Use of exercise or pharmacologic stress testing
in combination with imaging.
Recommend atio ns Class a Level b
An imaging stress test is recom mend ed as the in itial 
test for diagnos ing SC AD if th e PTP is betw een 66 –
85% or if LVEF is <50 % in patients without
typic al angina
I B
An imaging stress test is recom mend ed in  patients 
with rest ing ECG abn ormali ties whi ch pr event 
accurate in terpretation o f ECG changes duri ng stress
I B
Exercise str ess test ing is recom mend ed rath er than
pharm acol ogic t est ing whenever possib le.
I C
An i maging stress test should be  cons idered in
symp tomatic p atients w ith prior  revascula rization (P CI 
or CABG)
IIa B
An imaging stress test should be cons idered to  assess
the fun ction al sev eri ty of in term ediat e lesions on
coron ary art eriography.
Iia B
CABG = coronary artery bypass graft; ECG = electrocardiogram;
PCI = percutaneous coronary intervention; PTP = pre-test probabil-
ity; SCAD = stable coronary artery disease.
aClass of recommendation.
bLevel of evidence.
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will be false. Thus, the Task Force recommends no testing in
patients with a low PTP < 15% or high PTP > 85% (Table 9).
Patients with a reduced left ventricular ejection fraction
(LVEF) of <50% and typical angina are at high risk for
cardiovascular events and they should be offered ICA without
previous testing (Fig. 1). Patients with an intermediate PTP of
15–85% should undergo further non-invasive testing (Fig. 2).
Further testing may, however, be indicated for stratiﬁcation of
risk of events, especially if no satisfactory control of symptoms
is possible with initial medical therapy.
6.2.4. Stress testing for diagnosing ischaemia
6.2.4.1. Electrocardiogram exercise testing. The main diagnos-
tic ECG abnormality during ECG exercise testing consists of a
horizontal or down-sloping ST-segment depression 0.1 mV,
persisting for at least 0.06–0.08 s after the J-point, in one or
more ECG leads. The main value of exercise ECG testing is in
patients with normal resting ECGs. Inconclusive exercise ECGs
are common and in these patients an alternative non-invasive
imaging test often with pharmacological stress should be
selected. In patients at low intermediate pre-test probability,
coronary CTA is another option.
6.2.4.2. Stress imaging. Stress echocardiography is performed
with exercise (treadmill or bicycle ergometer) or with
pharmacological agents (Table 10). A pharmacological test is
preferred when there is already a signiﬁcant resting wall
motion abnormality (dobutamine for viability assessment)
and/or if the patient is unable to exercise adequately. Until
recently, stress echocardiography relied on inducible wall
thickening abnormalities as a marker of ischaemia (supply–
demand mismatch). The pharmacological agent of choice to
produce supply–demand mismatch is dobutamine.Myocardial perfusion scintigraphy (SPECT/PET): Technetium-
99m (99mTc) radiopharmaceuticals are the most commonly
used tracers, employed with single photon emission comput-
ed tomography (SPECT) in association with a symptom-limited
exercise test on either a bicycle ergometer or a treadmill
(Table 15). As with all stress imaging techniques, SPECT
perfusion also provides a more sensitive prediction of the
presence of CAD than the exercise ECG. Pharmacological stress
testing with perfusion scintigraphy is indicated in patients
who are unable to exercise adequately. MPI using positron
emission tomography (PET) is superior to SPECT imaging for
the detection of SCAD and may be used if available.
Stress cardiac magnetic resonance: CMR stress testing, in
conjunction with a dobutamine infusion, can be used to detect
wall motion abnormalities induced by ischaemia. The tech-
nique has been shown to have a comparable safety proﬁle to
dobutamine stress echocardiography (DSE).
Hybrid techniques: Hybrid SPECT/CT, PET/CT and PET/CMR
imaging are now available at a few selected centres. Hybrid
imaging is a novel technique combining functional and
anatomical aspects.
6.2.5. Non-invasive techniques to assess coronary anatomy
6.2.5.1. Computed tomography. Calcium scoring (without con-
trast injection) has no role in symptomatic patients for
diagnosing or excluding coronary stenosis. Coronary CT
angiography (CTA) can visualize the coronary artery lumen.
Since the speciﬁcity of coronary CTA decreases with increasing
amounts of coronary calcium, and the prevalence of coronary
artery stenosis was found to be high in symptomatic
individuals with an Agatston score >400, it is reasonable not
to proceed with coronary CTA if the calcium score exceeds 400.
Coronary CTA remains less reliable in patients with coronary
stents, due to artefacts caused by metal, the limited spatial
resolution of CT and overestimation of the degree of stenosis.
Registry data conﬁrm an excellent prognosis if coronary CTA
demonstrates the absence of coronary artery stenoses.
6.2.5.2. Magnetic resonance coronary angiography. This tech-
nique is primarily a research tool.
Fig. 1 – Initial diagnostic management of patients with suspected SCAD. CAD, coronary artery disease; CTA, computed
tomography angiography; CXR, chest X-ray; ECG, electrocardiogram; ICA, invasive coronary angiography; LVEF, left
ventricular ejection fraction; PTP, pre-test probability; SCAD, stable coronary artery disease.
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ICA may, however, be indicated following non-invasive risk
stratiﬁcation for determination of options for revasculariza-
tion. In patients who have a high PTP and severe symptoms, or
a clinical constellation suggesting high event risk, early ICA
without previous non-invasive risk stratiﬁcation maybe a good
strategy to identify lesions potentially amenable to revascu-
larization. FFR testing is advised if appropriate (Table 11).
6.4. Stratiﬁcation for risk of events
These guidelines provide a uniform deﬁnition of risk of
adverse events based on commonly used non-invasive testsand ICA. An annual mortality >3% is deﬁned as a high event
risk. It is in such patients that revascularization has the
potential effect of improving prognosis. Low event risk
patients are those with an annual mortality <1% whereas
the intermediate event risk group has an annual mortality of
1% but 3%/year.
The strongest predictor of long-term survival is LV function
and patients with an LVEF <50% are already at high risk for
events. Especially in patients with tolerable symptoms ICA
and revascularization should be reserved for those patients
found to be at high risk on the basis of non-invasive stress
testing. Patients with a high pre-test probability who do not
need diagnostic testing should nevertheless undergo stress
testing for event risk stratiﬁcation purposes.
Fig. 2 – Non-invasive testing in patients with suspected SCAD and an intermediate pre-test probability. CAD, coronary artery
disease; CTA, computed tomography angiography; CMR, cardiac magnetic resonance; ECG, electrocardiogram; ICA, invasive
coronary angiography; LVEF, left ventricular ejection fraction; PET, positron emission tomography; PTP, pre-test probability;
SCAD, stable coronary artery disease; SPECT, single photon emission computed tomography.
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performed using the Duke treadmill score (http://www.
cardiology.org/tools/medcalc/duke/).
When stress echocardiography is used, high event risk is
deﬁned by inducible wall motion abnormalities 3 of the 17
segments.
Stress-induced large reversible perfusion deﬁcits (SPECT)
>10% of the total LV myocardium (>2 of the 17 segments),Table 11 – Risk stratification by invasive or non-invasive
coronary arteriography in patients with stable coronary
artery disease.
Recommend atio ns Class a Level b
ICA (with  FFR when nec essary) is recom mend ed fo r risk str atifi cation 
in patients withj severe stable angina (CCS  3) or with  clinical profile 
suggest ing a high  event risk, particularly if the symp toms are 
inadequ ate ly responding to medical  treatment
I C
ICA (with  FFR when nec essary) is recom mend ed  in patients with mild 
or no symp toms with me dical  trea tme nt in whom non-invasive risk 
stratifi cation indica tes a hi gh  event risk and revasculartization is 
considered for improvement ofprognosis 
I C
ICA (with  FFR when nec essary)should be considered for event risk 
stratifica tion in patients with  an inconclusive diag nosis or non-invasive 
testing  or conflicting  resul ts from diffe rent non-invasive studies
IIa C
If coronary CTA is availa ble for event risk str atifica tion, possible 
oveestimation of stenosis severi ty should be cons idered in segments 
with severe ca lcifications. Additional stress ima ging may be necessary 
IIa C
CCS = Canadian Cardiovascular Society; CTA = computed tomogra-
phy angiography; FFR = fractional ﬂow reserve; ICA = invasive
coronary angiography; PTP = pre-test probability; SCAD = stable
coronary artery disease.
aClass of recommendation.
b Level of evidence.defects in multiple coronary territories or LV dilatation
represent a high risk subset.
High risk by stress CMR is deﬁned as new wall motion
abnormalities in 3 segments in the 17 segment model or as
>10% (>2 segments) perfusion defect. However, CMR risk
estimates are somewhat limited as only three slices of the LV
are currently available for standard CMR tests.
Good prognostic data exist for ICA and patients with left
main disease and proximal triple vessel disease are at high
risk.
6.5. Management aspects in the patient with known
coronary artery disease
The clinical course of patients with known SCAD may continue
to be stable or be complicated by phases of instability, MI and
heart failure. Re-assessment of the prognosis, following an
initial evaluation documenting a low event risk status may be
considered after the expiration of the period for which the test
is valid (Table 12).
6.6. Special diagnostic considerations: angina with
'normal' coronary arteries
Patients with microvascular angina have angina with mostly
typical features although the duration of symptoms may be
prolonged and relation to exercise is somewhat inconsistent.
Often, these patients have abnormal results of stress tests.
Patients with vasospastic angina present with typically
located anginal pain, which occurs at rest but does not—or
Table 12 – Re-assessment in patients with stable coronary
artery disease.
Recommend atio ns Class a Level b
Fol low -up visits are rec ommend ed  every 4–6 therapy fo r 
SCAD which m ay be extend ed to 1  year  afterwards. Vis its 
should b e to the general practition er  who m ay refer to th e 
cardiologis t in case of uncert ain ty. These visits should include
a ca reful his tory and biochemical  test ing as clinically 
appropri ate
I C
An annual r est ing ECG is recom mend ed and an additional 
ECG if a change in anginal status occurred or symptoms 
suggest ing an arrhyth mia appea red or medica tion  has be en 
changed which might alter  electric al cond uction.
I C
An exercise ECG or stress ima ging if appropri ate  is 
recom mend ed in the presence  of recurrent or new symp toms 
once instabi lity has bee n ruled out.
I C
Rea ssessment of the prognos is us ing stress testi ng may be 
considered in asymp tom atic patients afte r the expiration of the 
period  for wh ich the p revious  test was f elt to be valid
(“warranty period ”)
IIb C
Repetition of an  exercise ECG m ay only be considered  aft er at 
least 2 years  followin g the last test (unl ess there is a change in 
clinic al pre sentation)
IIb C 
ECG = electrocardiogram; SCAD = stable coronary artery disease.
aClass of recommendation.
bLevel of evidence.
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in the early morning hours). The ECG during vasospasm is
classically described as showing ST-elevation. Nitrates usually
relieve the pain within minutes. Angiographically, these
patients may show focal occlusive spasm (Prinzmetal's angina
or variant angina).
7. Lifestyle and pharmacological management
7.1. Lifestyle modiﬁcation
The aim of the management of SCAD is to reduce symptoms
and improve prognosis. The management of CAD patients
encompasses lifestyle modiﬁcation, control of CAD risk
factors, evidence-based pharmacological therapy and patient
education. Lifestyle recommendations include smoking ces-
sation a healthy diet, regular physical activity, weight and lipid
management, BP and glucose control.
Smoking is a strong and independent risk factor for CVD and
all smoking, including environmental smoking exposure,
must be avoided. Quitting smoking is complex because in
general, when smoking is both pharmacologically and
psychologically highly addictive.
A healthy diet reduces CVD risk. Healthy weight—is
BMI < 25 kg/m2. Following the rules for a healthy diet, no
dietary supplements are needed.
Regular physical activity is associated with a decrease in CV
morbidity and mortality in patients with CAD. Cardiac
rehabilitation is commonly offered after MI or recent coronary
intervention, but should be considered in all patients with
CAD, including those with chronic angina. Exercise training
should be advocated to improve exercise capacity and reduce
myocardial oxygen consumption.
Sexual activity is associated with an exercise workload of up
to 6 METS. Pharmacological therapy with phosphodiesterase
type 5 (PDES) inhibitors (sildenaﬁl, tadalaﬁl and vardenaﬁl) are
effective, safe and well tolerated in men with stable CAD.
However, use of nitric oxide donors, i.e. all of the preparations ofnitroglycerin as well as isosorbide mononitrate and isosorbide
dinitrate, are absolute contra-indications to use of PDES inhibi-
tors, because of the risk of synergistic effects on vasodilatation,
causing hypotension and haemodynamic collapse.
Hormone replacement therapy is at present not recommended
for primary or secondary prevention of CVD.
7.2. Pharmacological management of SCAD
The two aims of the pharmacological management are to
obtain relief of symptoms and to prevent CV events. Table 13
indicates the main side effects, contraindications and major
drug–drug interactions. Table 14 presents the recommenda-
tions for drug therapy.
7.2.1. Anti-ischaemic drugs
Nitrates offer coronary arteriolar and venous vasodilatation,
which are the basis of symptomatic relief of effort angina,
acting by their active component nitric oxide (NO) and by the
reduction of preload. For acute effort angina short-acting
nitrates as sublingual nitroglycerin is the standard initial
therapy. Nitroglycerin can be used prophylactically when
angina can be expected, such as activity after a meal,
emotional stress, sexual activity and in cold weather. For
angina prophylaxis long-acting nitrates are not continuously
effective. Thus prolonged therapy with isosorbide dinitrate or
isosorbide mononitrate is not evidence-based.
In post-MI patient b-blockers achieved a 30% risk reduction
for CV death and MI. b-blockers may be the ﬁrst line anti-
anginal therapy in stable CAD patients without contraindica-
tions. Nevibolol and bisoprolol are partly secreted by the
kidney, whereas carvedilol and metoprolol are metabolized by
the liver, hence being safer in patients with renal compromise.
Calcium channel blockers reduce the peripheral vascular
resistance. Group of non-dihydropyridine (heart rate-lowering
calcium channel blockers)—verapamil has a large range of
approved indications, including all varieties of angina (effort,
vasospastic, unstable), supraventricular tachycardias and
hypertension. Indirect evidence suggests good safety but with
risks of heart block, bradycardia and heart failure. Dihydro-
pyridines are powerful arterial vasodilators with a few serious
side-effects. However, the CCB and b-blocker combination is
often underused.
Ivabradine is a heart rate-lowering agent selectively inhibits
the sinus node I(f) pacemaking current, thereby decreases the
myocardial oxygen demand without effect on inotropism.
Ivabradine is thus an effective anti-anginal agent, alone or in
combination with b-blockers.
Nicorandil is a nitrate derivative of nicotinamide may be
added after b-blockers and CCBs. Long-term use of oral
nicorandil may stabilize coronary plaques. Occasional side-
effects include oral, intestinal and perianal ulceration.
Trimetazidine is an anti-ischaemic metabolic modulator.
Trimetazidine added to beta-blockade improved effort-in-
duced myocardial ischaemia.
Ranolazine is a selective inhibitor of late sodium channel
current with anti-ischaemic and metabolic properties. Rano-
lazine prolongs QTc.
Allopurinol, an inhibitor of xanthine oxidase reduces
vascular oxidative stress.
Table 13 – Major side-effects, contra-indications, drug–drug interactions (DDI) and precautions of anti-ischaemic drugs.
Drug class Side effectsa Contraindications DDI Precautions
Short-acting and
long-acting nitrates
Headache
Flushing
Hypotension
Syncope and postural
hypotension
Reﬂex tachycardia
Methaemoglobinaemia
Hypertrophic obstructive
cardiomyopathy
PDE 5 inhibitors
(sildenaﬁl or similar
agents)
a-Adrenergic blockers
CCBs
–
b-Blockersb Fatigue, depression
Bradycardia
Heart block
Bronchospasm
Peripheral vasoconstriction
Postural hypotension
Impotence
Hypoglycaemia/mask
hypoglycaemia signs
Low heart rate or heart
conduction disorder
Cardiogenic shock
Asthma
COPD caution; may use
cardioselective b-blockers if
fully treated by inhaled
steroids and long-acting
b-agonists
Severe PVD
Decompensated heart failure
Vasospastic angina
Heart-rate lowering CCB
Sinus-node or AV
Conduction depressors
Diabetics
COPD
CCBs: heart-rate
lowering
Bradycardia
Heart conduction defect
Low ejection fraction
Constipation
Gingival hyperplasia
Low heart rate or heart rhythm
disorder
Sick sinus syndrome
Congestive heart failure
Low BP
Cardiodepressant
(b-blockers, ﬂecainid)
CYP3A4 substrates
–
CCBs:
dihydropyridines
Headache
Ankle swelling
Fatigue
Flushing
Reﬂex tachycardia
Severe aortic stenosis
Obstructive cardiomyopathy
Cardiogenic shock
CYP3A4 substrates –
Ivabradine Visual disturbances
Headache, dizziness
Bradycardia
Atrial ﬁbrillation
Heart block
Low heart rate or heart rhythm
disorder
Allergy
Severe hepatic disease
QTc prolonging drugs
Macrolide antibiotics
Anti-HIV
Anti-fungal
Age >75 years
Severe renal
failure
Nicorandil Headache
Flushing
Dizziness, weakness
Nausea
Hypotension
Oral, anal, gastrointestinal
ulceration
Cardiogenic shock
Heart failure
Low blood pressure
PDE5 inhibitors
(sildenaﬁl or similar
agents)
–
Trimetazidine Gastric discomfort
Nausea
Headache
Movement disorders
Allergy
Parkinson disease
Tremors and movement
disorders
Severe renal impairment
None reported Moderate renal
impairment
Elderly
Ranolazine Dizziness
Constipation
Nausea
QT prolongation
Liver cirrhosis CYP450 substrates
(digoxin, simvastatin,
cyclosporine)
QTc prolonging drugs
–
Allopurinol Rash
Gastric discomfort
Hypersensitivity Mercaptopurine/azathioprine Severe renal failure
AV = atrioventricular; CCBs = calcium channel blockers; CHF = congestive heart failure; PVD = peripheral vascular disease, COPD = chronic
obstructive pulmonary disease; DDI = drug–drug interactions; HIV = Human Immunodeﬁciency virus; PDE5 = phosphodiesterase type 5.
a Very frequent or frequent; may vary according to speciﬁc drugs within the therapeutic class.
b Atenolol, metoprolol CR, bisoprolol, carvedilol.
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similar to those of isosorbide dinitrate.
Patients with low blood pressure or low heart rate should be
started at very low doses, with preferential use of drugs with
no- or limited impact on BP, HR, such as ivabradine (in patients
with sinus rhythm), ranolazine or trimetazidine.7.2.2. Event prevention
Antiplatelet agents are the key in prevention of ischaemic
events and low dose of aspirin is the drug of choice in most
cases, clopidogrel may be considered for some patients. The
use of antiplatelet agents is associated with a higher bleeding
risk. The optimal risk–beneﬁt ratio appears to be achieved with
Table 14 – Pharmacological treatments in stable coronary
artery disease patients.
Indi cation Class a Level b
General con sider atio ns
Optimal  medic al  treatment  indicates  at  least one  dru g fo r 
angina/ischae mia relief  plus dru gs for  event prevent ion
I  C
It  is recom mend ed to educate p atients about the disease, risk  factors  and 
treatment s trategy 
I  C 
It  is indicated to  revie w the patient’s respon se soon  aft er startin g therapy. I C
Angina/ ischaemiac relief
Short-ac ting nitrates  are recom mend ed I B
First -line treatment is ind icated  with ß-blockers  and/or calciu m channel 
blockers to control heart  rate  and symp toms
I A
For second-line treatment  it  is r ecom mend ed to add long-acting nitrates 
or ivabradine or nicorandil or ranolazine,  acc ording to heart  rate, blood 
pre ssure and tolerance
IIa B
For second-line treatment, trimet azid ine may be considered IIb B
Accordi ng to comorbidities/ tolerance it is indicated to us e second-line 
therapiesas fi rst line treatment in  sele cted p atients
I C
In asymp tomatic  patients with larg e area s of ischaemia (>10 %) ß-
blockers should be considered
IIa  C
In  patients w ith vasospastic angina, calcium c hannel blockers  and nitrates 
should be considered and beta -blockers  avoided
IIa  B
Event prevention
Low -dose aspirin daily is recom mend ed in all SC AD patients I  A
Clopido grel  is indic ated  as an  alternative in case of aspirin  into lerance I B
Statin s are recom mended in all  SCAD patients I A
It  is recom mend ed to use ACE inh ibi tors (or ARBs) if presence  of other 
conditions ( e.g.  heart  failure,  hypertensio n or diabetes)
I A
ACE = angiotensin converting enzyme; SCAD = stable coronary
artery disease.
aClass of recommendation.
bLevel of evidence.
cNo demonstration of beneﬁt on prognosis.
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thienopyridines act as antagonists of the platelet adenosine
diphosphate (ADP) receptor P2Y, thereby inhibiting platelet
aggregation. Clopidogrel is a second-line treatment for aspirin-
intolerant CVD patients. Prasugrel and ticagrelor are new P2Y12
antagonists that achieve greater platelet inhibition, compared
with clopidogrel. Dual antiplatelet therapy combining aspirin
and a thienopyridine is the standard of care for patients withFig. 3 – Medical management of patients with stable coronary art
CABG, coronary artery bypass graft; CCB, calcium channel block
dihydropyridine; PCI, percutaneous coronary intervention.ACS, including after the acute phase, when the patients are
stabilized, but cannot be recommended systematically in SCAD
patients. Platelet function testing in SCAD patients undergoing
PCI is not recommended as a routine.
SCAD patients should be treated with statin with a target of
LDL-C < 1.8 mmol/l and/or >50% reduction if the target level
cannot be reached.
ACE inhibitors reduce total mortality, MI stroke and heart
failure in patients with co-existing hypertension, LVEF  40%,
diabetes or CKD. ARB treatment may be an alternative when
ACE is not tolerated.
Aldosterone blockade with spironolactone or eplerenone is
recommended in post-MI patients without signiﬁcant renal
dysfunction or hyperkalaemia, who are already receiving
therapeutic doses of an ACE inhibitor and a b-blocker, have an
LVEF  40% and have either diabetes or heart failure.
Fig. 3 summarizes the medical management of SCAD
patients. It is recommended in the ﬁrst line a b-blocker or a
CCB to a short-acting nitrate.
7.3. Treatment of particular forms of SCAD
All patients with microvascular angina should achieve optimal
coronary risk factor control. Short-acting nitrates can be used
to treat anginal attacks, but often they are only partially
effective. b-blockers are recommended as ﬁrst line treatment,
calcium antagonists as second line. ACE inhibitors (ARBs) may
improve microvascular function. Xanthine derivatives (ami-
nophylline, bamiphylline) reduce angina by adenosine recep-
tor blockade.
All patients with vasospastic angina should achieve optimal
coronary risk factor control. A drug-related cause (e.g. cocaine or
amphetamines) should be systemically researched and man-
aged if detected. Chronic preventive treatment of vasospastic
angina is mainly based on the use of CCBs, usually prevent
spasm in about 90% of patients In about 10% of cases, coronaryery disease. ACEI, angiotensin converting enzyme inhibitor;
ers; CCS, Canadian Cardiovascular Society; DHP,
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with stent implantation at the site of spasm (even in the absence
of signiﬁcant stenosis), as well as chemical or surgical sympath-
ectomy have been reported but are not recommended. Because
of the high prevalence of silent ischaemic episodes and possible
arrhythmias 24-h ambulatory ECG monitoring can be used.
8. Revascularization
8.1. Percutaneous coronary intervention
8.1.1. Type of stent and dual antiplatelet therapy
Bare metal stents (BMS) are associated with a 20–30% rate of
angiographic stenosis within 6–9 months after implantation.
Drug-eluting stents (DES) reduce the incidence of restenosis and
ischaemia-driven repeat revascularization. The most recent
DES (with thinner struts and biodegradable or more biocompat-
ible polymers) showed superior clinical outcomes for both
efﬁcacy and safety and are therefore the recommended option
in SCAD patients with no contra-indication to DAPT (Table 15).
Clopidogrel pretreatment in stable patients undergoing
elective PCI does not reduce mortality or major adverse cardiac
events (MACE), but after stenting, premature discontinuation
of antiplatelet therapy is a major risk factor for stent
thrombosis. Current guidelines recommended 6–12 months
of DAPT after ﬁrst-generation DES and shorter duration of
DAPT with a latest-generation DES might be sufﬁcient in stable
coronary patients. Patients on concomitant anticoagulant
treatment the use of clopidogrel only has shown signiﬁcant
advantages in a single small-scale trial (WOEST).
8.1.2. Intracoronary assessment of stenosis severity
(fractional ﬂow reserve, intravascular ultrasound and optical
coherence tomography)
In patients with FFR > 0.80, studies in the BMS era have
demonstrated that medical treatment provides better outcomesTable 15 – Stenting and peri-procedural antiplatelet
strategies in stable coronary artery disease patients.
thrombosis on clopido grel without treatment interruption
GP II bIIIa ant agonists should be considered fo r bailout situation only  IIa  C
Platelet function testing or genetic testing may be considered in specific 
or high risk situations (e ,g prior history of stent thrombosis ; compliance 
issue; suspicion of resi stance; high bleedi ng risk) if  results m ay change 
the trea tment strategy
IIb C
Prasugrel or ticagre lor may be considered in spec ifi c high risk situations 
of ele ctive stenting (e.g. left  main stent ing, high risk of stent thrombosis; 
diabetes)
IIb C
Pretr eatment with  clopidogrel (when coronary anato my is not known) is 
not recom mend ed
III A
Routine platelet function testing (c lopidogrel and aspirin) to adjust 
ant iplatelet therapy befo re or after  elective stenting is not recom mend ed
III A
Prasugrel or ticagre lor is not recom mend ed in low  risk ele ctive stenting II I C
Recom mend ations Classa Levelb
DES is recom mend ed in SC AD patients undergoing stenting if there is 
no contraindica tion to prolonged DAPT
I  A
Aspirin is recom mend ed fo r elective stenting  I  B
Clopido grel  is recom mended for elect ive stenting  I  A
Prasugrel or ticagre lor should be considered in patients with stent  IIa  C
DATP = dual antiplatelet therapy; SCAD = stable coronary artery
disease.
aClass of recommendation.
bLevel of evidence.than immediate revascularization (low-risk population). The
recent fractional ﬂow reserve vs. angiography for multivessel
evaluation (FAME-2) study conﬁrmed that SCAD patients with
stenoses having FFR  0.80 gain a beneﬁt from PCI revasculari-
zation in addition to OMT. FFR measurement may change the
strategy and the extent of revascularization in multivessel
disease (PCI vs. CABG) and noncritical LM stenosis.
IVUS is far superior to FFR to provide an anatomical
characterization of the lesion in terms of vessel size and
plaque composition and can control stent expansion and strut
apposition. Previously accepted cut-off limits of minimal
luminal area of 3.5 or 4.0 mm2 for major epicardial artery
stenosis and 6.0 mm2 for left main stenosis have been shown
to be poorly correlated with FFR.
More recently, optical coherence tomography (OCT) has
been developed as a new intracoronary imaging tool with
superior resolution (<10 mm) able to offer detailed assessment
of superﬁcial components (presence of thrombus, stent
expansion and apposition, healing, ﬁbrous cap measurement).
8.2. Coronary artery bypass surgery
When technically feasible, with an acceptable level of risk and
a good life expectancy, revascularization is indicated in
chronic angina refractory to OMT
8.2.1. Arterial vs. venous grafts
For the last 25 years the principle technique has been the use of
an internal mammary artery (IMA) to the LAD coronary artery
with supplemental vein grafts as required. Angiographic
studies have conﬁrmed the superior patency of both IMA
grafts in comparison to vein grafts, this translate into a
survival beneﬁt and reduced incidence of MI, recurrent angina
and the need for repeat revascularization. Bilateral IMA
grafting reported a signiﬁcant survival beneﬁt with (OR 0.81)
especially in patients with diabetes. The radial artery has also
been proposed as a second arterial graft.
8.2.2. On-pump vs. off-pump surgery
Numerous randomized trials and meta-analyses have shown
no signiﬁcant beneﬁcial effect on mortality, reductions in
stroke, transfusion, re-operation for peri-operative bleeding
and postoperative complications, but at the cost of an excess of
repeat revascularization with off-pump CABG.
8.3. Revascularization vs. medical therapy
The decision to revascularize a patient should be based on
clinical judgement, severity of clinical symptoms, presence of
signiﬁcant obstructive coronary artery stenosis, the amount of
related ischaemia and expected beneﬁt to prognosis and/or
symptoms (Fig. 4). The Heart Team discussion should consider
the individual risk/beneﬁt ratio (Table 16).
8.3.1. Post-myocardial infarction
Small studies suggest beneﬁt of revascularization in patients
with a recent MI and silent myocardial ischaemia. No beneﬁt
was found in subset of patients with persistent total occlusion
of the infarct-related artery, and no angina or no residual
ischaemia. Systematic early PCI (within 24 h) post thrombolysis
Fig. 4 – Global strategy of intervention in stable coronary artery disease (SCAD) patients with demonstrated ischaemia. CABG,
coronary artery bypass graft; CAD, coronary artery disease; LAD, left anterior descending; LV, left ventricular; OMT, optimal
medical treatment; PCI, percutaneous coronary intervention.
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MI.
8.3.2. Left ventricular dysfunction
The LV dysfunction is one of the most powerful indicators of
an adverse prognosis and has become a prime target for
coronary revascularization. Several older studies suggested
that survival was improved by CABG over medical therapy in
patients with mild-to-moderate systolic dysfunction especial-
ly in association with triple vessel disease. The STICH trial of
subjects with EF < 35% demonstrated reduction of CV mortali-
ty and hospitalization for major CV causes in the CABG group.
8.3.3. Multivessel disease and/or large ischaemic territory
CABG enjoyed a better survival and lower rates of subsequent MI
and need for additional revascularization procedures over
medical therapy at a follow-up period of 10 years. In patients
with mild angina pectoris and triple vessel disease, survival
advantage was conﬁned to those with mild-to-moderate LV dys-
function. On the other hand, among patients with severe angina,
survival was improved irrespective of LV function. In addition,
the greater the number of proximal stenosis, the greater the
surgical beneﬁt. Observational studies also support a survival
advantage for CABG in patients with double-vessel disease in the
presence of severe or extensive ischaemia or severe angina.
8.3.4. Left main coronary artery disease
LM CAD (stenosis 50% or greater) continues to be a Class I
indication for revascularization due to the survival advantages
(VACS, CASS). No further randomized, controlled trials ofbypass surgery or PCI vs. medical therapy are likely to be
undertaken in patients with LM CAD.
8.4. Revascularization in lower-risk populations
The COURAGE trial compared PCI + OMT with OMT only. The
primary endpoint of all-cause death or non-fatal MI did not
differ. However, in patients who were invasively treated,
freedom from angina was signiﬁcantly better up to 3 years of
follow-up. More PCI + OMT patients exhibited signiﬁcant
ischaemia reduction and lower unadjusted risk for death or
MI, particularly if baseline ischaemia was moderate to severe.
The BARI-2D trial evaluated whether PCI or CABG combined
with OMT, would be better than OMT alone in patients with
type 2 diabetes mellitus and stenosis >70% presenting with
angina symptoms or positive stress test (30%) The all-cause
mortality, MI or stroke at 5 years follow-up did not differ
between the two treatment strategies. The patients with most
severe disease selected for CABG had reduction of MI
compared with OMT.
The FAME-2 trial randomized patients with functionally
signiﬁcant stenosis (FFR  0.80). The study was stopped
prematurely due to a highly signiﬁcant reduction in hospital
re-admission and urgent revascularization in the FFR  0.80-
PCI group, compared with the FFR  0.80-OMT group.
8.5. Limitations of the randomized studies
Typically, populations of these studies were selected after an
angiogram, had demonstrated at least one signiﬁcant stenosis
Table 16 – Indications for revascularization of stable
coronary artery disease patients on optimal medical
therapy (adapted from ESC/EACTS 2010 Guidelines).
A Heart Team ap pro ach  to r evasculari zation is 
recom mend ed in  patients w ith unprot ected left 
main, 2–3 v essel disea se, diabetes or comorbid ities
I C I C
Left main >50 % diameter stenos isb I A I A
Any pro ximal  LAD >50% diamete r stenosisb I A I A
2–3 vessel disea se with impaire d LV  function / 
CHF
I B IIa B
Sin gle remaini ng vessel  (>50%  diam eter stenos isb ) I C I A
Prov en large a rea of ischae mia  (> 10% LV c) I B I B
Any signifi cant s tenos is with limiting symp toms  or 
symp toms  not r espons ive/tole rant  to OMT
NA NA IIa B
Dyspn oea/c ardi ac heart  failure  with >10% 
ischaemia/v iabi lity c supplied by stenosi s >50%.
IIb B IIa B
No limitin g symp toms w ith OMT in v essel othe r 
than left main or p roximal LAD or single remaini ng 
vessel or vessel subtend ing area of ischaemia <10% 
of myocardium or  with  FFR ≥0.80
III A II I C
Indi cationa To 
improv e 
prognos is
To 
improv e 
symp toms 
persistent 
on 
OMT
Class d Level e eClass d Level
CCS = Canadian Cardiovascular Society; CHF = congestive heart
failure; FFR = fractional ﬂow reserve; LAD = left anterior descend-
ing; LV = left ventricle; NA = not available; OMT = optimal medical
treatment; SCAD = stable coronary artery disease.
aIn asymptomatic patients, the decision will be guided by the
extent of ischaemia on stress testing.
bWith documented ischaemia or FFR, 0.80 for angiographic
diameter stenoses 50–90%.
cAs assessed by non-invasive test (SPECT, MRI, stress echocardio-
graphy).
dClass of recommendation.
eLevel of evidence.
Fig. 5 – Percutaneous coronary intervention (PCI) or coronary art
disease without left main coronary artery involvement. CABG, c
PCI, percutaneous coronary intervention.
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ted myocardial ischaemia—with, in general, good LV function,
no comorbidities and excluding patients at high angiographic
risk, patients with LM coronary disease, CABG, multivessel
disease, or lesions deemed to be treated with revascularization
without further discussion for OMT only. Crossover rates from
OMT to revascularization were much higher than initially
expected (33–42%).
8.6. Percutaneous coronary intervention vs. coronary
artery bypass graft
In SYNTAX trial patients with three-vessel or left main
coronary artery disease were randomized to undergo CABG
or PCI. At 12 months higher rate of major adverse cardiac or
cerebrovascular events was in the PCI group, in large part
because of an increased rate of repeat revascularization. At 5
years, all-cause death was 13.9% with PCI, against 11.4% with
CABG (P = 0.10). This beneﬁt was driven only by the upper two
tertiles of the SYNTAX score; although PCI and CABG
performed as well on all endpoints for SYNTAX scores of 22
or less. The FREEDOM trial demonstrated a signiﬁcant
reduction on the primary ischaemic outcome at 5 years in
diabetic patients with multivessel disease treated with CABG
vs. PCI.
For patients with three-vessel disease when they present
with a syntax score 22 or when complete revascularization is
not achievable by PCI or when they have diabetes CABG should
be the preferred option in patients that are eligible for surgery
(Fig. 5).
In SYNTAX, the results patients with LMS disease showed
no overall difference between CABG and PCI in terms of deathery bypass graft surgery (CABG) in stable coronary artery
oronary artery bypass graft; LAD, left anterior descending;
Fig. 6 – Percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) in stable coronary artery disease
with left main coronary artery involvement. CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.
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revascularization was higher with stents (P = 0.004). Another
study (PRECOMBAT) reported a composite endpoint of death,
cerebrovascular accident and MI as 4.7% for CABG and 4.4% for
PCI. Meanwhile, angiographic characteristics of the LM disease
are key in selection between PCI and CABG (calciﬁcations,
ostial/mid/distal, LM size, distal lesions, etc.) and, for lower
severity of LMS disease, PCI produces at least equivalent—if
not superior—outcomes to CABG (Fig. 6).
9. Special groups or considerations
9.1. Women
Coronary artery disease develops 5–10 years later in women
than in men. Stable angina is the most common initial
presentation, but twice as often as men have no signiﬁcant
obstructive CAD. Women have higher rates of procedural
complication, including mortality, stroke and vascular com-
plications. At present HRT is not recommended for primary or
secondary prevention of CVD.
9.2. Patients with diabetes
Mortality due to CVD is increased three-fold in diabetic men and
two- to ﬁve-fold in diabetic women. A target HbA1c <7%
(<53 mmol/mol) and target blood pressure <140/85 mmHg are
recommended. Coronary artery revascularization of diabetics
remains a challenge. The decision to use either PCI or CABG as
preferred mode of revascularization should be based on
anatomical factors, together with clinical factors and other
logistical or local factors (Fig. 6). As a rule, PCI is recommended in
diabetic patient with single-vessel disease. CABG in diabeticpatients with multivessel disease after discussion in a Heart
Team meeting.
9.3. Patients with chronic kidney disease
Chronic kidney disease is a risk factor for CAD and has a major
impact on outcomes and therapeutic decisions. The use of drugs
and iodinated contrast agents is exposes patients to more
complications. This is also a group of patients poorly explored in
clinical trials, with limited strong evidence based medicine.
9.4. Elderly patients
This population is speciﬁc for higher prevalence of comorbid-
ities, atypical symptoms difﬁculties in performing stress
testing and higher risk of complications during and after
coronary revascularization.
9.5. Repeat revascularization of the patient with prior
CABG
PCI may be preferred in patients with discrete lesions in grafts
and preserved LV function or accessible native vessel disease.
Repeat bypass surgery may be preferred when the vessels are
unsuitable for PCI and when there are good distal vessel
targets for bypass graft placement.
10. Gaps in evidence
These guidelines suffer from limitations inherent in the
evidence available, uncertainties on the best imaging modali-
ties, on what is the best modern pharmacologic approach and on
what is the real beneﬁt from myocardial revascularization.
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